modelL04AE01

Diagram of L04AE01

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Fingolimod
ATC code:L04AE01
route:oral
compartments:2
dosage:0.5mg
volume of distribution:1200L
clearance:6.3L/h
other parameters in model implementation

Fingolimod is an oral sphingosine 1-phosphate receptor modulator approved for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and delay disability progression. It is currently widely used for this purpose.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after oral administration. Population is both sexes, ages 18-55.

References

  1. David, OJ, et al., & Schmouder, RL (2012). Clinical pharmacokinetics of fingolimod. Clinical pharmacokinetics 51(1) 15–28. DOI:10.2165/11596550-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22149256

  2. Wu, K, et al., & Looby, M (2012). Population pharmacokinetics of fingolimod phosphate in healthy participants. Journal of clinical pharmacology 52(7) 1054–1068. DOI:10.1177/0091270011409229 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22110161

  3. Baldin, E, & Lugaresi, A (2020). Ponesimod for the treatment of relapsing multiple sclerosis. Expert opinion on pharmacotherapy 21(16) 1955–1964. DOI:10.1080/14656566.2020.1799977 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32808832

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)